Abstracts tagged "systemic lupus erythematosus (SLE) and vitamins"

Abstract Number: 2687 • 2012 ACR/ARHP Annual Meeting
Modular Microarray Analysis Fails to Reveal a Significant Biological Effect of Vitamin D3 Treatment in Patients Participating in a Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Michaela Oswald¹, Cynthia Aranow², Diane L. Kamen³, Meggan C. Mackay⁴, Ellen A. Goldmuntz⁵, Betty Diamond⁶, Peter K. Gregersen⁷ and ALE02 Study Team⁸, ¹Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, NY, ³Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵DAIT, NIAID/NIH, Bethesda, MD, ⁶Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ⁷Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸NIAID/NIH Rm 6807, Bethesda, MD
Background/Purpose: Vitamin D modulates the immune response. Exposing normal PBMCs to activating SLE sera induces an interferon signature which can be inhibited by preexposure of…
Abstract Number: 2619 • 2012 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Cynthia Aranow¹, Maria Dall'era², Elena M. Massarotti³, Meggan C. Mackay⁴, Andreea Coca⁵, Fotios Koumpouras⁶, Marc C. Levesque⁷, W. Winn Chatham⁸, Megan E. B. Clowse⁹, Lisa G. Criscione-Schreiber¹⁰, Sherri Callahan¹¹, Ellen A. Goldmuntz¹², Lynette Keyes-Elstein¹³, Betty Diamond¹⁴ and Diane L. Kamen¹⁵, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁶Lupus Center of Excellence, West Penn Hospital, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Rheumatology, Duke University Health System, Durham, NC, ¹¹Dait, NIAID/NIH Rm 6807, Bethesda, MD, ¹²DAIT, NIAID/NIH, Bethesda, MD, ¹³Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ¹⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Exposure of normal PBMCs to1,25 OH vitamin D reverses the stimulatory effects of activating SLE sera on the interferon signature. Given that IFN is…
Abstract Number: 691 • 2012 ACR/ARHP Annual Meeting
Characterization of Pro-Inflammatory Cytokines and Vitamin D Levels in a Lupus Cohort and Correlation with Disease Activity
Rohan Willis¹, Praveen Jajoria¹, Brock E. Harper², Emilio B. Gonzalez³, Michelle Petri⁴, Ehtisham Akhter⁵, Hong Fang⁴ and Silvia S. Pierangeli¹, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multiple cytokines play a role in the immune dysregulation seen in systemic lupus erythematosus (SLE) and the local inflammatory responses that ultimately lead to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].